Estimation of Level of ERAP1 Expression in Lesional and Non Lesional Skin of Psoraitic Patients and Healthy Controls.

Not Applicable

Completed

• Conditions: Psoriasis

• Registration Number: NCT03767114
• Lead Sponsor: Kasr El Aini Hospital

Brief Summary

A 4mm Punch biopsy is obtained from lesional and non lesional skin of 25 psoraitic patients as well as of 30 controls.

Skin biopsy from patients (psoriasis lesional and non lesional) \& control will be kept in lysis solution (which contains RNAase inhibitor) for the stability of the parameter to be assessed. ERAP-1 gene expression will Research Template 5 Final Version: 8/3/2 016 be detected by quantitative real time -PCR, which include RNA extraction, cDNA synthesis \& PCR.

Detailed Description

Not available

Study Timeline

• Study Start: 2017-01
• Primary Completion: 2017-06
• Status Verified: 2018-12
• Study Completion: 2018-12
• Study First Submitted: 2018-12-05
• Study First Submitted QC: 2018-12-05
• Last Update Submitted: 2018-12-05
• Study First Posted: 2018-12-06
• Last Update Posted: 2018-12-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 55

Inclusion Criteria

• patients with psoriasis vulgaris
• patients over 18 years of age
• both sexes

Exclusion Criteria

• patients on treatment for psoriasis within the last two months
• assoiciated autoimmune diseases eg SLE
• pregnancy

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Estimation of lesional ERAP1 in psoriatic skin	Maximum 2 years	DPCRetection of level of expression of ERAP 1 in lesional skin of psoriasis patients by RT-

Secondary Outcome Measures

Name	Time	Method
Estimation of non lesional ERAP1 in psoriatic skin	Maximum 2 years	Detection of level of expression of ERAP 1 in non lesional skin of psoriasis patients by RT-PCR.